Literature DB >> 8044659

Difference in frequencies of the cystic fibrosis alleles, delta F508 and W1282X, between carriers and patients.

Y M Kalman1, E Kerem, A Darvasi, J DeMarchi, B Kerem.   

Abstract

One major mutation, delta F508, causing cystic fibrosis (CF) is found in most populations around the world. Among CF patients of Jewish Ashkenazi origin two major mutations, W1282X and delta F508 were found. We compared the relative frequencies of the two major mutations found in this patient population to their relative frequencies in the healthy population. The studied patient population included the entire CF Jewish Ashkenazi patient population in Israel (238 chromosomes), and a small group of Jewish Ashkenazi patients in the USA (57 chromosomes). Among these, 79 (27%) chromosomes carried the delta F508 mutation, and 151 (51%) the W1282X mutation. In addition, we have analyzed the results of screening 1,946 unrelated healthy Jewish Ashkenazi individuals for the delta F508 and the W1282X mutations. Surprisingly, an almost equal number of carriers of the delta F508 (35) and W1282X (36) was found. The difference between the relative proportions of the mutations in the two groups is statistically significant (p = 0.025). A striking manifestation of this difference is revealed in the analysis of patients' genotypes. There were 36 patients homozygous for W1282X, while only 7 patients were homozygous for delta F508, although the number of delta F508 carriers in the general Jewish Ashkenazi population is almost equal to the number of W1282X carriers. This difference in allele frequencies found between healthy carriers and CF patients in the Jewish Ashkenazi population might not be unique to this ethnic group nor to the CF disease. The results indicate that the common practice of inferring general population epidemiologic parameters directly from patients information is liable to introduce biases.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1994        PMID: 8044659     DOI: 10.1159/000472347

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  4 in total

Review 1.  Targeted therapy for cystic fibrosis: cystic fibrosis transmembrane conductance regulator mutation-specific pharmacologic strategies.

Authors:  Ronald C Rubenstein
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

2.  Highly variable incidence of cystic fibrosis and different mutation distribution among different Jewish ethnic groups in Israel.

Authors:  E Kerem; Y M Kalman; Y Yahav; T Shoshani; D Abeliovich; A Szeinberg; J Rivlin; H Blau; A Tal; L Ben-Tur
Journal:  Hum Genet       Date:  1995-08       Impact factor: 4.132

3.  Ethnic Differences in the Frequency of CFTR Gene Mutations in Populations of the European and North Caucasian Part of the Russian Federation.

Authors:  Nika Petrova; Natalia Balinova; Andrey Marakhonov; Tatyana Vasilyeva; Nataliya Kashirskaya; Varvara Galkina; Evgeniy Ginter; Sergey Kutsev; Rena Zinchenko
Journal:  Front Genet       Date:  2021-06-16       Impact factor: 4.599

4.  HIV-1 and Human PEG10 Frameshift Elements Are Functionally Distinct and Distinguished by Novel Small Molecule Modulators.

Authors:  Tony S Cardno; Yosuke Shimaki; Brad E Sleebs; Kurt Lackovic; John P Parisot; Rebecca M Moss; Caillan Crowe-McAuliffe; Suneeth F Mathew; Christina D Edgar; Torsten Kleffmann; Warren P Tate
Journal:  PLoS One       Date:  2015-10-08       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.